Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence

Stock Information for Sera Prognostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sera Prognostics Inc.

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
Quanterix Releases Financial Results for the Third Quarter of 2025
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.